The UK and US have finalized a important trade agreement that will keep zero levies on British drug shipments going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase funding on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will remain at nothing for a timeframe of three years.
This agreement follows earlier statements to hike duties on patented pharmaceutical imports, with increases mentioned reaching one hundred percent.
"This deal with the Britain reinforces the international landscape for cutting-edge drugs and introduces long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Trade Importance
Pharmaceuticals are one of the UK's biggest goods shipped to the America, which is easily the largest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months to the end of September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that span.
"This agreement safeguards jobs, boosts funding and paves the way for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement involves several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments topped twenty percent.
Recent Tensions
This agreement follows a ongoing row between the drug companies and the British authorities over medicine costs and regulatory access.
This friction were heightened by claims that US consumers were paying significantly more for the same drugs than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been halted or scrapped, while substantial expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had declined as a share of its overall budget over the previous ten-year period.
